This Annex sets out the information requirements that shall be included in the dossier for the biocidal product accompanying an application for the approval of an active substance in accordance with point (b) of Article 6(1) and the dossier accompanying an application for the authorisation of a biocidal product in accordance with point (a) of Article 20(1).
The data elements set down in this Annex comprise a Core Data Set (CDS) and an Additional Data Set (ADS). The data elements belonging to the CDS are considered as the basic data which should, in principle, be provided for all biocidal products.
With regard to the ADS, the data elements to be provided for a specific biocidal product shall be determined by considering each of the ADS data elements indicated in this Annex taking into account, inter alia, the physical and chemical properties of the product, existing data, information which is part of the CDS and the types of products and the exposure patterns related to these uses.
Specific indications for the inclusion of some data elements are provided in column 1 of the Annex III table. The general considerations regarding adaptation of information requirements as set out in Annex IV to this Regulation shall also apply. In light of the importance of reducing testing on vertebrates, column 3 of the table gives specific indications for the adaptation of some of the data elements which might require the use of such tests on vertebrates.
For some of the information requirements set out in this Annex, it may be possible to satisfy these requirements based on available information of the properties of the active substance(s) contained in the product and the properties of non-active substance(s) included in the product. For non-active substances, applicants shall use the information provided to them in the context of Title IV of Regulation (EC) No 1907/2006, where relevant, and the information made available by the Agency in accordance with point (e) of Article 77(2) of that Regulation. However, the information may be not sufficient or adequate to determine whether a non-active substance contained in a biocidal product has hazardous properties and the evaluating body may conclude that further data are required.
The relevant calculation methods used for the classification of mixtures as laid down in Regulation (EC) No 1272/2008 shall, where appropriate, be applied in the hazard assessment of the biocidal product. Such calculation methods shall not be used if, in relation to a particular hazard, synergistic and antagonistic effects between the different substances contained in the product are considered likely.
Detailed technical guidance regarding the application of this Annex and the preparation of the dossier is available on the website of the Agency.
The applicant shall initiate a pre-submission consultation with the prospective evaluating body. In addition to the obligation set out in Article 62(2), the applicant may also consult with the competent authority that will evaluate the dossier with regard to the proposed information requirements and in particular the testing on vertebrates that the applicant proposes to carry out. The applicant shall document such pre-submission consultations and their outcomes and shall include the relevant documents in the application.
Additional information may need to be submitted if necessary to carry out the evaluation as indicated in Article 29(3) or Article 44(2).
The information submitted shall, in any case, be sufficient to support a risk assessment demonstrating that the criteria in Article 19(1)(b) are met.
A detailed and full description of studies conducted and of the methods used shall be included. It is important to ensure that the data available is relevant and is of sufficient quality to fulfil the requirements.
The formats made available by the Agency shall be used for submission of the dossiers. In addition, IUCLID shall be used for those parts of the dossiers to which IUCLID applies. Formats and further guidance on data requirements and dossier preparation are available on the Agency homepage.
Tests submitted for the purpose of authorisation shall be conducted in accordance with the methods described in Commission Regulation (EC) No 440/2008, or any revised version of these methods not yet included in that Regulation.
However, if a method is inappropriate or not described in Commission Regulation (EC) No 440/2008, [Commission Regulation (EC) No 440/2008 of 30 May 2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) (OJ L 142, 31.5.2008, p. 1).] other methods shall be used which are scientifically appropriate and their appropriateness shall be justified in the application.
When test methods are applied to nano-materials, an explanation shall be provided of their scientific appropriateness for nanomaterials, and where applicable, of the technical adaptations or adjustments that have been made in order to respond to the specific characteristics of these materials.
Tests performed should comply with the relevant requirements of protection of laboratory animals, set out in Directive 2010/63/EU and, in the case of ecotoxicological and toxicological tests, good laboratory practice, set out in Directive 2004/10/EC or other international standards recognised as being equivalent by the Commission or the Agency. Tests on physico-chemical properties and safety-relevant substance data should be performed at least according to international standards.
Where testing is done, a detailed quantitative and qualitative description (specification) of the product used for each test and its impurities must be provided.
Where test data exist that have been generated before 17 July 2012 by methods other than those laid down in Regulation (EC) No 440/2008, the adequacy of such data for the purposes of this Regulation and the need to conduct new tests according to the Regulation (EC) No 440/2008 must be decided by the competent authority of the Member State, on a case-by-case basis, taking into account, among other factors, the need to avoid unnecessary testing.
New tests involving vertebrates shall be conducted as the last available option to comply with the data requirements set out in this Annex when all the other data sources have been exhausted. In vivo testing with corrosive substances at concentration/dose levels causing corrosivity shall also be avoided.
Information required to support the authorisation of a biocidal product is listed in the table below.
For each information requirement set down in this Annex the indications given in columns 1 and 3 of Annex II for the same information requirement shall also apply.
[Eye-irritation test shall not be necessary where the biocidal product has been shown to have potential corrosive properties.]
Column 1
Information required:
Column 2
All data is CDS unless indicated as ADS
Column 3
Specific rules for adaptation from column 1
APPLICANT
1.1. Name and address, etc.
1.2. Contact person
1.3. Manufacturer and formulator of the biocidal product and the active substance(s) (names, addresses, including location of plant(s))
IDENTITY OF THE BIOCIDAL PRODUCT
2.1. Trade name or proposed trade name
2.2. Manufacturer’s development code and number of the product, if appropriate
2.3. Complete quantitative (g/kg, g/l or % w/w (v/v)) composition of the biocidal product, i.e. declaration of all active substances and non-active substances (substance or mixture according to Article 3 of Regulation (EC) No 1907/2006), which are intentionally added to the biocidal product (formulation) as well as detailed quantitative and qualitative information on the composition of the active substance(s) contained in the biocidal product. For non-active substances, a safety data sheet in compliance with Article 31 of Regulation (EC) No 1907/2006 has to be provided.
In addition, all relevant information on individual ingredients, their function and, in the case of a reaction mixture, the final composition of the biocidal product shall be given
2.4. Formulation type and nature of the biocidal product, e.g. emulsifiable concentrate, wettable powder, solution
2.5. Where the biocidal product contains an active substance that has been manufactured in locations or according to processes or from starting materials other than those of the active substance evaluated for the purpose of approval pursuant to Article 9 of this Regulation, evidence has to be provided that technical equivalence has been established in accordance with Article 54 of this Regulation or has been established, following an evaluation having started before 1 September 2013, by a competent authority designated in accordance with Article 26 of Directive 98/8/EC
PHYSICAL, CHEMICAL AND TECHNICAL PROPERTIES
3.1. Appearance (at 20 °C and 101,3 kPa)
3.1.1. Physical state (at 20 °C and 101,3 kPa)
3.1.2. Colour (at 20 °C and 101,3 kPa)
3.1.3. Odour (at 20 °C and 101,3 kPa)
3.2. Acidity/alkalinity
The test is applicable when the pH of the biocidal product or its dispersion in water (1 %) is outside the pH range 4-10
3.3. Relative density (liquids) and bulk, tap density (solids)
3.4. Storage stability, stability and shelf-life
3.4.1. Storage stability tests
3.4.1.1. Accelerated storage test
3.4.1.2. Long term storage test at ambient temperature
3.4.1.3. Low temperature stability test (liquids)
3.4.2. Effects on content of the active substance and technical characteristics of the biocidal product
3.4.2.1. Light
3.4.2.2. Temperature and humidity
3.4.2.3. Reactivity towards container material
3.5. Technical characteristics of the biocidal product
3.5.1. Wettability
3.5.2. Suspensibility, spontaneity and dispersion stability
3.5.3. Wet sieve analysis and dry sieve test
3.5.4. Emulsifiability, re-emulsifiability and emulsion stability
3.5.5. Disintegration time
3.5.6. Particle size distribution, content of dust/fines, attrition, friability
3.5.7. Persistent foaming
3.5.8. Flowability/Pourability/Dustability
3.5.9. Burning rate — smoke generators
3.5.10. Burning completeness — smoke generators
3.5.11. Composition of smoke — smoke generators
3.5.12. Spraying pattern — aerosols
3.5.13. Other technical characteristics
3.6. Physical and chemical compatibility with other products including other biocidal products with which its use is to be authorised
3.6.1. Physical compatibility
3.6.2. Chemical compatibility
3.7. Degree of dissolution and dilution stability
3.8. Surface tension
3.9. Viscosity
PHYSICAL HAZARDS AND RESPECTIVE CHARACTERISTICS
4.1. Explosives
4.2. Flammable gases
4.3. Flammable aerosols
4.4. Oxidising gases
4.5. Gases under pressure
4.6. Flammable liquids
4.7. Flammable solids
4.8. Self-reactive substances and mixtures
4.9. Pyrophoric liquids
4.10. Pyrophoric solids
4.11. Self-heating substances and mixtures
4.12. Substances and mixtures which in contact with water emit flammable gases
4.13. Oxidising liquids
4.14. Oxidising solids
4.15. Organic peroxides
4.16. Corrosive to metals
4.17. Additional physical indications of hazard
4.17.1. Auto-ignition temperatures of products (liquids and gases)
4.17.2. Relative self-ignition temperature for solids
4.17.3. Dust explosion hazard
METHODS OF DETECTION AND IDENTIFICATION
5.1. Analytical method including validation parameters for determining the concentration of the active substance(s), residues, relevant impurities and substances of concern in the biocidal product
5.2. In so far as not covered by Annex II 5.2 and 5.3, analytical methods for monitoring purposes including recovery rates and the limits of determination of relevant components of the biocidal product and/or residues thereof, where relevant in or on the following:
ADS |
5.2.1. Soil
ADS |
5.2.2. Air
ADS |
5.2.3. Water (including drinking water) and sediment
ADS |
5.2.4. Animal and human body fluids and tissues
ADS |
5.3. Analytical methods for monitoring purposes including recovery rates and the limit of quantification and detection for the active substance, and for residues thereof, in/on food of plant and animal origin or feeding stuffs and other products where relevant (not necessary if neither the active substance nor the material treated with it come into contact with food- producing animals, food of plant and animal origin or feeding stuffs)
ADS |
EFFECTIVENESS AGAINST TARGET ORGANISMS
6.1. Function, e.g. fungicide, rodenticide, insecticide, bactericide
Mode of control e.g. attracting, killing, inhibiting
6.2. Representative organism(s) to be controlled and products, organisms or objects to be protected
6.3. Effects on representative target organisms
6.4. Likely concentration at which the active substance will be used
6.5. Mode of action (including time delay)
6.6. The proposed claims for the product and, where claims are made, for treated articles regarding the biocidal properties conferred to the article
6.7. Efficacy data to support these claims, including any available standard protocols, laboratory tests or field trials used including performance standards where appropriate and relevant
6.8. Any known limitations on efficacy
6.8.1. Information on the occurrence or possible occurrence of the development of resistance and appropriate management strategies
6.8.2. Observations on undesirable or unintended side-effects on non-target organisms or on objects and material to be protected
6.9. Summary and evaluation
INTENDED USES AND EXPOSURE
7.1. Field(s) of use envisaged for biocidal products and, where appropriate, treated articles
7.2. Product-type
7.3. Detailed description of intended use pattern(s) for biocidal products and, where appropriate, treated articles
7.4. User e.g. industrial, trained professional, professional or general public (non-professional)
7.5. Likely tonnage to be placed on the market per year and, where relevant, for different use categories
7.6. Method of application and a description of this method
7.7. Application rate and, if appropriate, the final concentration of the biocidal product and active substance in a treated article or in the system in which the product is to be used, e.g. cooling water, surface water, water used for heating purposes
7.8. Number and timing of applications, and where relevant, any particular information relating to geographical location or climatic variations including necessary waiting periods, clearance times, withdrawal periods or other precautions to protect human health, animal health and the environment
7.9. Proposed instructions for use
7.10. Exposure data in conformity with Annex VI to this Regulation
7.10.1. Information on human exposure associated with production and formulation, proposed/expected uses and disposal
7.10.2. Information on environmental exposure associated with production and formulation, proposed/expected uses and disposal
7.10.3. Information on exposure from treated articles including leaching data (either laboratory studies or model data)
7.10.4. Information regarding other products that the product is likely to be used together with, in particular the identity of the active substances in these products, if relevant, and the likelihood of any interactions
TOXICOLOGICAL PROFILE FOR HUMANS AND ANIMALS
8.1. Skin corrosion or irritation
The assessment shall comprise the following tiers:
assessment of the available human, animal and non-animal data;
skin corrosion, in vitro testing;
skin irritation, in vitro testing;
skin corrosion or irritation, in vivo testing
Testing of the product or mixture does not need to be conducted if:
there are sufficient valid data on each component of the product or mixture to allow its classification in accordance with Regulation (EC) No 1272/2008, and synergistic effects between any of the components are not expected,
the product or mixture is a strong acid (pH≤ 2,0) or base (pH≥ 11,5),
the product or mixture is spontaneously flammable in air or in contact with water or moisture at room temperature,
the product or mixture meets the classification criteria for acute toxicity category 1 by the dermal route, or
an acute toxicity study by the dermal route provides conclusive evidence on skin corrosion or irritation adequate for classification.
If results from one of the two studies listed in points (b) or (c) in column 1 of this row already allow conclusive decision on the classification of product or mixture or on the absence of skin irritation potential, the second study does not need to be conducted
An in vivo study for skin corrosion or irritation shall be considered only if the in vitro studies listed in points (b) and (c) in column 1 of this row are not applicable, or the results of these studies are not adequate for classification and risk assessment and the calculation method or bridging principles laid down in Regulation (EC) No 1272/2008 are not applicable
In vivo studies for skin corrosion or irritation that were carried out or initiated before 15 April 2022 shall be considered appropriate to address this information requirement
8.2. Serious eye damage or eye irritation
The assessment shall comprise the following tiers:
assessment of the available human, animal and non-animal data;
serious eye damage or eye irritation, in vitro testing;
serious eye damage or eye irritation, in vivo testing
Testing on the product or mixture does not need to be conducted if:
there are sufficient valid data available on each component of the product or mixture to allow its classification in accordance with Regulation (EC) No 1272/2008, and synergistic effects between any of the components are not expected,
the product or mixture is a strong acid (pH≤ 2,0) or base (pH≥ 11,5),
the product or mixture is spontaneously flammable in air or in contact with water or moisture at room temperature, or
the product or mixture meets the classification criteria for skin corrosion leading to its classification as ‘serious eye damage’ category 1
If results from a first in vitro study do not allow a conclusive decision on the classification of the product or mixture or on the absence of eye irritation potential (an)other(s) in vitro study(ies) for this endpoint shall be considered
An in vivo study for serious eye damage or eye irritation shall be considered only if the in vitro study(ies) under point (b) in column 1 of this row are not applicable, or the results obtained from these studies are not adequate for classification and risk assessment and the calculation method or bridging principles laid down in Regulation (EC) No 1272/2008 are not applicable
In vivo studies for serious eye damage or eye irritation that were carried out or initiated before 15 April 2022 shall be considered appropriate to address this information requirement
8.3. Skin sensitisation
The information shall allow to conclude whether the substance is a skin sensitiser and whether it can be presumed to have the potential to produce significant sensitisation in humans (Category 1A). The information should be sufficient to perform a risk assessment where required
The assessment shall comprise the following tiers:
assessment of the available human, animal and non-animal data;
skin sensitisation, in vitro testing. Information from in vitro or in chemico test method(s) conducted in accordance with point 5 of the introductory part of this Annex and addressing each of the following key events of skin sensitisation:
molecular interaction with skin proteins;
inflammatory response in keratinocytes;
activation of dendritic cells.
skin sensitisation in vivo testing. The Murine Local Lymph Node Assay (LLNA) is the first-choice method for in vivo testing. Another skin sensitisation test may only be used in exceptional circumstances. If another skin sensitisation test is used, scientific justification shall be provided.
Testing on the product or mixture does not need to be conducted if:
there are sufficient valid data available on each component of the product or mixture to allow its classification in accordance with Regulation (EC) No 1272/2008, and synergistic effects between any of the components are not expected,
the available information indicates that the product or mixture should be classified for skin sensitisation or skin corrosion,
the product or mixture is a strong acid (pH≤ 2,0) or base (pH≥ 11,5), or
the product or mixture is spontaneously flammable in air or in contact with water or moisture at room temperature.
In vitro tests do not need to be conducted if:
an in vivo study referred to in point (c) in column 1 of this row is available, or
the available in vitro or in chemico test methods are not applicable for the product or mixture or the results obtained from these studies are not adequate for classification and risk assessment.
If information from test method(s) addressing one or two of the key events described in point (b) in column 1 of this row already allows for classification of the substance and risk assessment, studies addressing the other key event(s) do not need to be conducted
An in vivo study for skin sensitisation shall be considered only if in vitro or in chemico studies referred to in point (b) in column 1 of this row are not applicable, or the results obtained from these studies are not adequate for classification and risk assessment and the calculation method or bridging principles laid down in Regulation (EC) No 1272/2008 are not applicable
In vivo studies for skin sensitisation that were carried out or initiated before 15 April 2022 shall be considered appropriate to address this information requirement
8.4. Respiratory sensitisation
ADS |
Testing on the product/mixture does not need to be conducted if:
there are valid data available on each of the components in the mixture to allow classification of the mixture according to the rules laid down in Directive 1999/45/EC and Regulation (EC) No 1272/2008 (CLP), and synergistic effects between any of the components are not expected
8.5. Acute toxicity
Classification using the tiered approach to classification of mixtures for acute toxicity in Regulation (EC) No 1272/2008 is the default approach
Testing on the product/mixture does not need to be conducted if:
there are valid data available on each of the components in the mixture to allow classification of the mixture according to the rules laid down in Directive 1999/45/EC and Regulation (EC) No 1272/2008 (CLP), and synergistic effects between any of the components are not expected
8.5.1. By oral route
8.5.2. By inhalation
8.5.3. By dermal route